Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-PSMA PET/MRI for Prostate Cancer Diagnosis
NCT05815316Phase 2Withdrawn
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Apr 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of radelumin in prostate cancer (PCa), sponsored by IRCCS Ospedale San Raffaele. Planned start Apr 2023; status: withdrawn.
02
Drugs
radelumin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05815316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05815316.